Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rutherford

Showing results (541-550 of 603) with videos related to

Pageof 61
Sort By:
Neurology|February 15, 2013
CSF1R mutations link POLD and HDLS as a single disease entityAlexandra M Nicholson, Matt C Baker, Nicole A Finch, et al.
Acta Neuropathologica|April 29, 2015
A truncating SOD1 mutation, p.Gly141X, is associated with clinical and pathologic heterogeneity, including frontotemporal lobar degenerationMasataka Nakamura, Kevin F Bieniek, Wen-Lang Lin, et al.
British Journal of Cancer|September 15, 2011
Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumabP Todeschini, E Cocco, S Bellone, et al.
Cancer Medicine|June 4, 2014
T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivoDiana P English, Stefania Bellone, Carlton L Schwab, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 15, 2011
Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibodyRhoda Raji, Federica Guzzo, Luisa Carrara, et al.
International Journal of Cancer|May 1, 2021
The impact of reclassifying cancers of unspecified histology on international differences in survival for small cell and non-small cell lung cancer (ICBP SurvMark-2 project)Eileen Morgan, Melina Arnold, Mark J Rutherford, et al.
Heart (British Cardiac Society)|December 30, 2025
Impact of a recent cancer diagnosis on bleeding risk after myocardial infarctionKok Weng Ow, Freya Tyrer, Freek Van Den Berg, et al.
Cancer|September 25, 2014
Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivoDiana P English, Stefania Bellone, Carlton L Schwab, et al.
British Journal of Cancer|October 1, 2014
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivoC L Schwab, S Bellone, D P English, et al.
Clinical & Experimental Metastasis|November 16, 2014
T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2Roberta Nicoletti, Salvatore Lopez, Stefania Bellone, et al.
Pageof 61

Showing results (541-550 of 603) with videos related to

Sort By:
Pageof 61
Neurology|February 15, 2013
CSF1R mutations link POLD and HDLS as a single disease entityAlexandra M Nicholson, Matt C Baker, Nicole A Finch, et al.
Acta Neuropathologica|April 29, 2015
A truncating SOD1 mutation, p.Gly141X, is associated with clinical and pathologic heterogeneity, including frontotemporal lobar degenerationMasataka Nakamura, Kevin F Bieniek, Wen-Lang Lin, et al.
British Journal of Cancer|September 15, 2011
Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumabP Todeschini, E Cocco, S Bellone, et al.
Cancer Medicine|June 4, 2014
T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivoDiana P English, Stefania Bellone, Carlton L Schwab, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 15, 2011
Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibodyRhoda Raji, Federica Guzzo, Luisa Carrara, et al.
International Journal of Cancer|May 1, 2021
The impact of reclassifying cancers of unspecified histology on international differences in survival for small cell and non-small cell lung cancer (ICBP SurvMark-2 project)Eileen Morgan, Melina Arnold, Mark J Rutherford, et al.
Heart (British Cardiac Society)|December 30, 2025
Impact of a recent cancer diagnosis on bleeding risk after myocardial infarctionKok Weng Ow, Freya Tyrer, Freek Van Den Berg, et al.
Cancer|September 25, 2014
Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivoDiana P English, Stefania Bellone, Carlton L Schwab, et al.
British Journal of Cancer|October 1, 2014
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivoC L Schwab, S Bellone, D P English, et al.
Clinical & Experimental Metastasis|November 16, 2014
T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2Roberta Nicoletti, Salvatore Lopez, Stefania Bellone, et al.
Pageof 61